Meeting
2022 ASCO Annual Meeting
Primary analysis from the phase 2 study of continuous talazoparib (TALA) plus intermittent low-dose temozolomide (TMZ) in patients with relapsed or refractory extensive-stage small cell lung cancer (ES-SCLC).
Authors
Jonathan W. Goldman
David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA
Jonathan W. Goldman , Amy Lauren Cummings , Melody A. Mendenhall , Maria A Velez , Sunil Babu , Tirrell T. Johnson , Juan M. Alcantar , Shaker R. Dakhil , David E. Kanamori , William E. Lawler , Sidharth Anand , James Chauv , Edward B. Garon , Dennis J. Slamon
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Small Cell Lung Cancer
Clinical Trial Registration Number
NCT03672773
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 8517)
DOI
10.1200/JCO.2022.40.16_suppl.8517
Abstract #
8517
Poster Bd #
144
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Two schedules of vincristine, irinotecan and temozolomide (VIT) for patients with relapsed or refractory Ewing sarcoma: A randomized controlled phase 2 trial.
First Author: Jie Xu
Poster
2022 ASCO Annual Meeting
Circulating tumor DNA (ctDNA) mutations associate with response in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) treated with talazoparib (TALA) and temozolomide (TMZ).
First Author: Maria A Velez
Poster
2021 ASCO Annual Meeting
Circulating tumor DNA (ctDNA) mutations may predict treatment response in extensive-stage small cell lung cancer (ES-SCLC) treated with talazoparib and temozolomide (TMZ).
First Author: Matthew C Mulroy
Poster
2016 ASCO Annual Meeting
A multi-center, randomized, double-blind phase II study comparing temozolomide (TMZ) plus either veliparib (ABT-888), a PARP inhibitor, or placebo as 2nd or 3rd-line therapy for patients (Pts) with relapsed small cell lung cancers (SCLCs).
First Author: Maria Catherine Pietanza